ARTICLE | Company News
BioTransplant transplant news
November 18, 2002 8:00 AM UTC
BTRN said it plans to partner, divest or close all programs and assets aside from MEDI-507. Last month, BTRN partner MedImmune Inc. (MEDI, Gaithersburg, Md.) delayed by about a year the start of Phase III testing of their MEDI-507 antibody to treat psoriasis (see BioCentury, Oct. 28). Also, BTRN gave all employees a tentative notice of future termination. ...